Whalesbook
Okay, toh yeh GLP-1 market jo diabetes aur weight loss ke liye important hai, iska bazaar tezi se fail raha hai. Pharma data bata raha hai ki April mein semaglutide drugs ki sales 51% badh kar ₹88 crore ho gayi. Isse GLP-1 market mein inka share 33% se 40% ho gaya.
Ab dekho, Ozempic aur Wegovy jaisi branded drugs ki bhi unit sales lagbhag 39% badhi hain ( 23,000 se 32,000 units). Iska reason hai ki doctor aur kuch patients abhi bhi branded medicines ko prefer karte hain, unhe lagta hai ki ye zyada effective hain. Is wajah se, branded semaglutide revenue stable hai. April mein innovator aur generic semaglutide ne ₹44 crore revenue share kiya.
Lekin asli hero toh generics hain! Patent khatam hone ke baad jab 25+ generic semaglutide versions aaye, toh generic units 242% bhag gaye, matlab 40,000 se seedha 137,000 units! Yeh sab affordability ki wajah se hua hai, taaki zyada patients tak ye important medicines pahunch sakein.
Market mein sabse aage Eli Lilly (LLY) aur Novo Nordisk (NVO) hain. Eli Lilly ka market cap $918 billion ke aas paas hai aur iska P/E ratio 34.6 hai. Inki Mounjaro aur Zepbound drugs ki wajah se Q1 2026 mein $19.8 billion revenue aaya. Analysts mostly positive hain, target price $1217 ke aas paas hai.
Dusri taraf, Novo Nordisk ka market cap $157 billion hai aur P/E 12.6 hai, jo kaafi kam hai. Shayad market ko lagta hai ki Lilly ke saamne competition mushkil hai. Novo Nordisk ne bhi Q1 2026 mein achha kiya, lekin analyst ratings 'Hold' par aa gayi hain, pehle 'Moderate Buy' thi.
Abhi toh innovator drugs ka revenue achha hai, par generic semaglutide ka volume growth prices par pressure daal raha hai. Future mein branded drugs ke prices kam ho sakte hain. Medicare bhi 2027 mein in drugs ke prices negotiate karega. Eli Lilly ke Foundayo oral drug se jude liver failure reports bhi ek risk hai, haalanki yeh isolated case ho sakta hai. Direct-to-consumer discounts bhi pricing ko affect kar rahe hain.
Aage ke liye, Eli Lilly ne apna 2026 revenue forecast $82-85 billion kar diya hai, Mounjaro aur Zepbound ki demand ke karan. Novo Nordisk ne bhi apna outlook improve kiya hai. Lekin market conditions ko dekhte hue, Eli Lilly ko 'Moderate Buy' rating mili hai jabki Novo Nordisk ko 'Hold'. Overall, GLP-1 market mein opportunities hain, par competition aur pricing ka game interesting rahega.